Andrew Mcusic, PhD (Drew) is a Venture Associate at Union Heritage Ventures, where he sources, selects, and supports early-stage investments and works closely with portfolio companies across healthcare, climate, mobility, and advanced manufacturing. Drew brings more than a decade of experience as an operator and product leader building and scaling companies through critical stages of growth, from early product development to commercialization and successful exits.

Prior to joining Union Heritage, Drew held senior operating and product leadership roles at Michigan-based companies including Theoria Medical and Swift Biosciences. At Theoria Medical, a technology-enabled healthcare services company later backed by private equity, he served as Chief Technology Officer and VP of Product, helping guide the organization through rapid growth, EHR software development and interoperability, and operational scale. His work included deploying AI and machine learning systems to support clinical decision-making, clinical outcomes prediction, operational efficiency, and scalable service delivery. Earlier, at Swift Biosciences, a Michigan-based, venture-backed genomics company acquired by Danaher’s IDT division, Drew led product initiatives supporting the development and commercialization of next-generation DNA sequencing technologies, applying product management frameworks to improve customer outcomes and sales traction. Across these roles, he has focused on translating technical innovation into scalable products, navigating regulated environments, and building durable go-to-market strategies.

In parallel with his operating work, Drew has partnered closely with early-stage founders through accelerator and fellowship programs, contributing to diligence, founder development, and ecosystem-building efforts. He brings a particular interest in how emerging AI and generative technologies can be responsibly applied to improve forecasting, automation, and interventional decision support across regulated and industrial sectors. This experience reinforced his belief that effective early-stage investing combines rigorous analysis with hands-on support and long-term partnership, particularly in capital-intensive or regulated markets.

Drew holds a PhD in Bioengineering from the University of Washington and a Bachelor of Science in Bioengineering from Rice University. He is also Pragmatic Institute PMC-III certified in product management. He approaches investing through a “planetary health, local impact” lens, viewing healthcare access, environmental sustainability, and economic resilience as deeply interconnected. Drew is particularly interested in backing companies that apply transformational technologies to improve human and environmental outcomes while creating durable jobs and economic opportunity.